Analgesia in Knee Arthroscopic Surgery

Postoperative Pain Clinical Trial

Official title:

Intra-articular Dexamethasone vs Intra-articular Dexamedetomidine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02818985
• Other study ID #: SM2016
• Status: Completed
• Phase: Phase 2
• First received: June 28, 2016
• Last updated: June 23, 2017
• Start date: June 2016
• Est. completion date: February 2017

Study information

• Verified date: June 2017
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pain relief in knee Arthroscopic Surgery is essential for rapid recovery of function.

Description:

Intra-articular analgesia is useful in reducing patients' postoperative disability. It anticipates and prevents the onset of pain, and helps avoid the need for additional drugs. Usually it is possible to reach good analgesia in the immediate postoperative period by the administration of analgesic drugs. Recently, intra-articular administration of different anaesthetic substances with a local action (e.g. bupivacaine) has been introduced in clinical practice. The aim of the administration of these substances should not be the reduction of postoperative pain, but its prevention.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: February 2017
• Est. primary completion date: February 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

• Patients scheduled for knee arthroscopy under spinal anaesthesia

Exclusion Criteria:

• Diabetes Mellitus

• Contraindication to spinal anesthesia

• Patient refusal

Related Conditions & MeSH terms

• Pain, Postoperative
• Postoperative Pain

Intervention

Drug:
• Dexamethasone
patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
• Dexmedetomidine
patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
• Saline
patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.

Locations

Country	Name	City	State
Egypt	Seham Mohamed Moeen Ibrahim	Asyut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pain free time	VAS	48 hours